FDA warns Empower Pharmacy for 3rd time over GLP-1 drugs tirzepatide & semaglutide, citing copies of brand-name treatments & ...
USTR hears testimony for and against tariffs on German-made drugs as nine European pharma chairs press EU governments on ...
“In some ways, it’s good that it’s out there now, and now we have a working plan to work towards quarter by quarter,” the Novo CEO told Endpoints News in a face-to-face meeting in London on ...
Vertex's inaxaplin showed 42.7% UACR reduction in AMKD patients with modest proteinuria. AMPLITUDE enrollment complete; interim data expected early 2027. $VRTX jumped 12%.
Viking Therapeutics' VK2735 patients maintained 85% of weight loss after switching to monthly dosing. Shares rose 20%. Phase 3 programs advancing; oral trial launching soon.
Celldex's barzolvolimab hits the mark in two Phase 3 chronic hives trials, but two anaphylaxis cases send shares down 12%.
Iambic Therapeutics has filed to go public and says it could move IAM1363, its lead drug targeting HER2 cancers, into a ...
Insurers plan to significantly increase AI budgets from 6% in 2024 to 31% in 2026, per Define Ventures' Lynne Chou O'Keefe, ...
ARPA-H's Advocate program funds AI systems for heart failure care, with Kaiser Permanente, Duke, Atman Health & UpDoc, facing trust & safety hurdles.
Roche says its enicepatide hit weight and blood sugar goals in a Phase 2 diabetes trial, with the top dose driving 15.5% weight loss.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results